Reuters |
FDA staff finds no new safety problems with Glaxo's asthma drug
Business Insider (Reuters) – GlaxoSmithKline Plc's respiratory treatment for chronic breathing problems did not show any new safety problems in treating asthma, a preliminary review by U.S. Food and Drug Administration staff found. The review comes two days ahead of a … Ad Comm meeting approaches for expanded indication for Glaxo's COPD med … |
View full post on asthma – Google News